5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline-3-carboxylic acid | 185563-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline-3-carboxylic acid
• 英文别名: 5-[4-[(1-Tritylimidazol-2-yl)amino]butyl]-4,5-dihydro-1,2-oxazole-3-carboxylic acid
• CAS: 185563-95-5
• 化学式: C₃₀H₃₀N₄O₃
• 分子量: 494.593
• InChiKey: KJIUNGWNHFXTKF-UHFFFAOYSA-N

物化性质

• 沸点：
  695.5±65.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  88.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline-3-carboxylic acid 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 (S)-2-Benzenesulfonylamino-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid
  参考文献：
  名称：

  Isoxazolines as Potent Antagonists of the Integrin α_vβ₃

  摘要：

  Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.

  DOI：

  10.1021/jm9900321
• 作为产物：
  描述：

  3-ethoxycarbonyl-5-(4-hydroxybutyl)isoxazoline 在 lithium hydroxide 、 草酰氯 、 三乙酰氧基硼氢化钠 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 47.0h， 生成 5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline-3-carboxylic acid
  参考文献：
  名称：

  Isoxazolines as Potent Antagonists of the Integrin α_vβ₃

  摘要：

  Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.

  DOI：

  10.1021/jm9900321

文献信息

• Integrin receptor antagonists
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05710159A1

  公开（公告）日：1998-01-20

  This invention relates to novel heterocycle compounds including but not limited to 3-\x9b3-\x9b3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.

  这项发明涉及新型杂环化合物，包括但不限于3-（咪唑啉-2-基氨基）丙氧基异噁唑-5-基甲酰氨基-2-（苄氧羰基氨基）丙酸，这些化合物可用作αvβ3及相关整合素受体的拮抗剂，以及含有这些化合物的药物组合物、制备这些化合物的方法，以及使用这些化合物单独或与其他治疗剂联合用于抑制细胞粘附和治疗血管生成障碍、炎症、骨质破坏、肿瘤、转移、血栓形成和其他细胞聚集相关疾病的方法。
• [EN] ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'ISOXAZOLINE ET D'ISOXADOLE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE L'INTEGRINE
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：WO1996037492A1

  公开（公告）日：1996-11-28

  (EN) This invention relates to novel heterocycle compounds including but not limited to 3-[3-[3-(imidazolin-2-yl amino)propyloxy]isoxazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the $g(a)v$g(b)3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.(FR) Cette invention se rapporte à de nouveaux composés hétérocycliques comprenant notamment, mais pas exclusivement, l'acide 3-[3-[3-(imidazoline-2-yl- amino)propyloxy]isoxasol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)-propionique et qui sont utilisés comme antagonistes des récepteurs $g(a)v$g(b)b3 et de l'intégrine apparentée. L'invention se rapporte également aux compositions pharmaceutiques contenant ces composés, aux procédés de préparation et d'utilisation de ces composés, seuls ou associés à d'autres agents thérapeutiques et destinés à être utilisés dans des procédés d'inhibition de l'adhésion cellulaire et de traitement de troubles angiogéniques, des inflammations, de la déperdition osseuse, des tumeurs, des métastases, de la thrombose et d'autres états apparentés à l'agrégation cellulaire.

  本发明涉及新型杂环化合物，包括但不限于3-[3-[3-(咪唑啉-2-基氨基)丙氧基]异噁唑-5-基甲酰胺]-2-(苄氧羰基氨基)丙酸，其作为$g(a)v$g(b)3和相关整合素受体的拮抗剂，以及含有这种化合物的制药组合物、制备这种化合物的过程，以及使用这些化合物的方法，单独或与其他治疗剂联合使用，用于抑制细胞黏附和治疗血管生成障碍、炎症、骨质破坏、肿瘤、转移、血栓形成和其他与细胞聚集相关的疾病。
• ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0828737A1

  公开（公告）日：1998-03-18
• Isoxazolines as Potent Antagonists of the Integrin α_vβ₃
  作者：William J. Pitts、John Wityak、Joanne M. Smallheer、A. Ewa Tobin、James W. Jetter、Jennifer S. Buynitsky、Patricia P. Harlow、Kimberly A. Solomon、Martha H. Corjay、Shaker A. Mousa、Ruth R. Wexler、Prabhakar K. Jadhav

  DOI：10.1021/jm9900321

  日期：2000.1.1

  Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.